We herein develop the cuproptosis and disulfidptosis co-delivery targeted (Cadict) nanodrug, an epidermal growth factor receptor (EGFR)-targeted nanoplatform designed to co-induce cuproptosis and disulfidptosis, thereby synergistically augmenting tumor cytotoxicity and sensitizing cancers to anti-PD-L1 therapy. This evidence concerns the gene CD274 and cancer.